Hormone receptor positive HER2 negative breast cancer
Not recruitingStudy of Patritumab Deruxtecan with or without Endocrine Therapy for High-Risk HR+/HER2- Early Breast Cancer in Untreated Patients
Study of Patritumab Deruxtecan with or without Endocrine Therapy for High-Risk HR+/HER2- Early Breast Cancer in Untreated Patients
- Disease:Hormone receptor positive HER2 negative breast cancer
- Substances:Patritumab Deruxtecan
Spain- Participants:18–64 years · 65+ years
- Substances:Patritumab Deruxtecan
- Sponsor:Solti Group







